MedTrace Logo

Safety and Efficacy of rAAV.hCNGA3 Gene Therapy in Patients With CNGA3-linked Achromatopsia

NCT02610582 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2024-04-18

No results posted yet for this study

Summary

The purpose of this study is to proof the safety and efficacy of a single bilateral subretinal injection of rAAV.hCNGA3 in adult and minor patients with CNGA3-linked achromatopsia.

Conditions

  • Achromatopsia

Interventions

DRUG

rAAV.hCNGA3

Single subretinal injection of rAAV.hCNGA3

Sponsors & Collaborators

  • University Hospital Tuebingen

    collaborator OTHER

  • Ludwig-Maximilians - University of Munich

    collaborator OTHER

  • STZ eyetrial

    lead OTHER

Principal Investigators

  • Dominik Fischer, Prof. · University Hospital Tuebingen, Center for Ophthalmology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2027-06-30
Completion
2027-06-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02610582 on ClinicalTrials.gov